.jpg?format=webp&width=780)
The study revealed acalabrutinib's noninferiority in progression-free survival and fewer adverse events (AEs) compared to ibrutinib in prior-treated patients. Post hoc examination of common AEs and clinically significant events (ECIs) unveiled higher incidence and burden of AEs like diarrhea, arthralgia, and infections with ibrutinib. Conversely, acalabrutinib exhibited higher rates of headache and cough. Acalabrutinib also demonstrated lower AE-related discontinuation rates and overall AE burden.
Like
Save
Share